Document Detail


The Role of Tc-99m-DTPA Nuclear Medicine GFR Studies in Pediatric Solid Tumor Patients.
MedLine Citation:
PMID:  22767127     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND:: Technetium-99m-diethylene-triamine-pentaacetate (Tc-99m-DTPA) nuclear medicine studies allow for accurate monitoring of glomerular filtration rate (GFR) in cancer patients receiving chemotherapy. However, these scans may be logistically challenging and are associated with some radiation exposure. OBJECTIVES:: The purpose of this study was to retrospectively review the use of Tc-99m-DTPA studies to evaluate the subgroup of children with low GFR by Tc-99m-DTPA who may most benefit from this procedure-namely, the patients with a normal serum creatinine (SCr) and GFR estimated by Schwartz (Sch) calculation who may otherwise not have their renal dysfunction recognized. We further determined how the GFR result modified the treatment plan for these patients. METHODS:: Patients aged 2 to 18 years with solid tumors diagnosed from 2000 to 2007 were identified. Tc-99m-DTPA results, corresponding height and SCr, were recorded and GFR Sch calculated. The clinical course of patients with Tc-99m-DTPA <80 mL/min/1.73 m and a normal SCr and GFR Sch were reviewed in detail. RESULTS:: Of 714 Tc-99m-DTPA studies in 231 patients, 41 (5.7%) in 24 patients (10.4%) reported a GFR result of <80 mL/min/1.73 m. Of those 41 studies, 16 (39%, 13 patients) were associated with normal SCr and normal GFR Sch. Of these 13 patients, 11 (85%) had 1 or more clinical risk factors suggestive of preexisting renal disease. Three patients had modifications to their chemotherapy. CONCLUSIONS:: There were few abnormal Tc-99m-DTPA results reported in this population. The majority of patients with abnormal Tc-99m-DTPA studies and normal SCr had clinical risk factors for renal dysfunction. A future prospective study may better help to define oncology patients for whom Tc-99m are essential for estimating renal function.
Authors:
Paul Gibson; Amer Shammas; Michaela Cada; Christoph Licht; Abha A Gupta
Related Documents :
8441237 - Lipoprotein heterogeneity in end-stage renal disease.
22358237 - Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis an...
21990267 - De novo 5q14.3 translocation 121.5-kb upstream of mef2c in a patient with severe intell...
20961187 - Serum paraoxonase 1 (pon1) lactonase activity is lower in end-stage renal disease patie...
24052027 - Upper limb robot-assisted therapy in chronic and subacute stroke patients: a kinematic ...
18632817 - Assessment of the influence of atrial fibrillation on gated spect perfusion data by com...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-2
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  -     ISSN:  1536-3678     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
*Department of Pediatrics, London Health Sciences Center, London Divisions of †Radiology ‡Hematology/Oncology §Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Parent-controlled PCA for pain management in pediatric oncology: is it safe?
Next Document:  Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.